JP2025509769A5 - - Google Patents

Info

Publication number
JP2025509769A5
JP2025509769A5 JP2024555187A JP2024555187A JP2025509769A5 JP 2025509769 A5 JP2025509769 A5 JP 2025509769A5 JP 2024555187 A JP2024555187 A JP 2024555187A JP 2024555187 A JP2024555187 A JP 2024555187A JP 2025509769 A5 JP2025509769 A5 JP 2025509769A5
Authority
JP
Japan
Prior art keywords
domain
ltbr
modified
nucleic acid
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064452 external-priority patent/WO2023178187A2/en
Publication of JP2025509769A publication Critical patent/JP2025509769A/ja
Publication of JP2025509769A5 publication Critical patent/JP2025509769A5/ja
Pending legal-status Critical Current

Links

JP2024555187A 2022-03-15 2023-03-15 改善した免疫療法のための融合タンパク質を含む方法及び組成物 Pending JP2025509769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320100P 2022-03-15 2022-03-15
US63/320,100 2022-03-15
PCT/US2023/064452 WO2023178187A2 (en) 2022-03-15 2023-03-15 Methods and compositions comprising fusion proteins for improved immunotherapies

Publications (2)

Publication Number Publication Date
JP2025509769A JP2025509769A (ja) 2025-04-11
JP2025509769A5 true JP2025509769A5 (https=) 2026-03-24

Family

ID=88024439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555187A Pending JP2025509769A (ja) 2022-03-15 2023-03-15 改善した免疫療法のための融合タンパク質を含む方法及び組成物

Country Status (10)

Country Link
US (1) US20250195572A1 (https=)
EP (1) EP4493201A4 (https=)
JP (1) JP2025509769A (https=)
KR (1) KR20250005563A (https=)
CN (1) CN119343456A (https=)
AU (1) AU2023236288A1 (https=)
CA (1) CA3245638A1 (https=)
IL (1) IL315188A (https=)
MX (1) MX2024011334A (https=)
WO (1) WO2023178187A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242168A1 (en) * 2024-05-22 2025-11-27 Nanjing Legend Biotech Co., Ltd. Methods of making cells expressing an engineered receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6821688B2 (ja) * 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドMiltenyi Biotec Technology, Inc. キメラ抗原受容体および使用方法
US12083148B2 (en) * 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
KR20220030205A (ko) * 2019-02-08 2022-03-10 디앤에이 투포인토 인크. 면역 세포의 트랜스포존 기반 변형
CN114080452B (zh) * 2019-06-27 2025-06-03 优特力克斯有限公司 具有4-1bb共刺激结构域的嵌合抗原受体
KR20220062305A (ko) * 2019-09-16 2022-05-16 맥마스터 유니버시티 키메라 공자극 수용체 및 이의 방법 및 용도

Similar Documents

Publication Publication Date Title
KR102946697B1 (ko) 키메라 분자 및 그의 용도
US20210269502A1 (en) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
AU2024205827A1 (en) Expression of novel cell tags
JP2021530217A5 (https=)
JP2002509430A (ja) Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド
CN110357953B (zh) 识别人巨细胞病毒pp65抗原的TCR
KR20200138741A (ko) 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
JP2021525534A5 (https=)
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
KR20180043841A (ko) 키메라 항원 수용체 및 이의 용도
JPH06501456A (ja) 表面複合リンホトキシン
JP2018512154A5 (https=)
JP2005523681A5 (https=)
JP2023527613A (ja) G12v変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP2025509769A5 (https=)
CN116239692B (zh) 分离的抗体、包含该抗体的car及其用途
RU2757353C1 (ru) NK-клеточная линия, экспрессирующая PSMA-специфический химерный антигенный рецептор и секретирующая блокатор взаимодействия CD47/SIRPa
JPH06510419A (ja) インターフェロン−γに誘発されるモノカイン−MIG
JPH07505524A (ja) Ifn受容体認識因子,そのタンパク質配列および使用方法
CN111100875B (zh) TGF-β受体II同种型、融合肽、治疗方法和体外方法
WO2005024027A1 (ja) 抗体医薬
EP4382119A1 (en) A kit for use in the treatment of hematological cancer
CN117165568B (zh) 工程化改造的psd蛋白、细胞外囊泡及其制备方法和应用
CN104961833A (zh) 一种人源NKp80-Fc融合蛋白及其制备方法和在肿瘤治疗中的应用
EP4566619A1 (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal